SECURITIES AND EXCHANGE COMMISSION

 

WASHINGTON, D.C. 20549

 

 

 

SCHEDULE 13G

(Rule 13d-102)

Under the Securities Exchange Act of 1934

 

INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES

13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. )*

 

ARNO THERAPEUTICS, INC.

(Name of Issuer)

 

COMMON STOCK

(Title of Class of Securities)

 

042564203

(CUSIP Number)

 

12/31/2013

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed.

 

¨ Rule 13d-1(b)

 

x Rule 13d-1(c)

 

¨ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Page 1 of 5 Pages

 

 
 

 

CUSIP No. 042564203 SCHEDULE 13G Page 2 of 5 Pages

 

1

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

FROST GAMMA INVESTMENTS TRUST

 

    46-0464745

 

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) ¨

(b) ¨

3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

FLORIDA

 


NUMBER OF
5 SOLE VOTING POWER 2,062,500 (1)

SHARES

BENEFICIALLY

6 SHARED VOTING POWER 0
OWNED BY
EACH
7 SOLE DISPOSITIVE POWER 2,062,500 (1)
REPORTING
PERSON WITH
8 SHARED DISPOSITIVE POWER 0

9 2,062,500 (1)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHRES*

 

¨

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

9.48%

12

TYPE OF REPORTING PERSON*

oo

 

(1) Includes 687,500 shares of common stock and warrants to purchase 1,375,000 shares of common stock.

 

 
 

 

CUSIP No. 042564203 SCHEDULE 13G Page 3 of 5 Pages

 

Item 1(a). Name of Issuer.  Arno Therapeutics, Inc.
   
Item 1(b). Address of Issuer’s Principal Executive Offices.
  4 Campus Drive, 2 nd Floor
  Parsippany, NJ  07054
   
Item 2(a). Name of Person Filing.
   
  Frost Gamma Investments Trust
   
Item 2(b). Address of Principal Business Office or, if None, Residence.
  4400 Biscayne Boulevard
  Miami, FL  33137
   
Item 2(c). Citizenship.
   
  The Trust is established in Florida
   
Item 2(d). Title of Class of Securities.
   
  Common Stock
   
Item 2(e). CUSIP Number.
   
  042564203
   
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), identify the status of the person filing.
   
  Not Applicable
   
Item 4. Ownership.

 

  (a)  Amount beneficially owned: 2,062,500 (1)
     
  (b)  Percent of class:    9.48% (2)

 

(c) Number of shares as to which such person has:

 

  (i) Sole power to vote or direct the vote:   2,062,500 (1)
  (ii) Shared power to vote or direct the vote:   0
       
  (iii) Sole power to dispose or direct the disposition of: 2,062,500 (1)
  (iv) Shared power to dispose or direct the disposition of:   0

 

(1) Includes 687,500 shares of common stock and warrants to purchase 1,375,000 shares of common stock.

(2) The percentage is calculated based upon the 20,370,331 shares of Common Stock issued and outstanding as of November 12, 2013 per the 10-Q f iled on November 14, 2013.

 

 
 

 

CUSIP No. 042564203 SCHEDULE 13G Page 4 of 5 Pages

 

Item 5. Ownership of Five Percent or Less of a Class.
   
  If this Statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.   ¨
   
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
   
  Not Applicable
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
   
  Not Applicable
   
Item 8. Identification and Classification of Members of the Group.
   
  Not Applicable
   
Item 9. Notice of Dissolution of Group.
   
  Not Applicable
   
Item 10. Certification.
   
  Not Applicable

 

 
 

 

CUSIP No. 042564203 SCHEDULE 13G Page 5 of 5 Pages

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

February 12, 2014 Frost Gamma Investments Trust
   
  /s/ Phillip Frost, MD
  By:     Phillip Frost, MD
   
  Title:  Trustee

 

 

 

Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Arno Therapeutics (CE) Charts.
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Arno Therapeutics (CE) Charts.